CTRI/2018/11/016295招募中3 期
A Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (GALNOBAX®) in Treating Diabetic Foot Ulcers.
ovaLead Pharma Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects, male or female, aged 18 to 65 years (inclusive) with Type 1 or Type 2 diabetes undergoing therapy for glycemic control
- •2.Subject has glycosylated hemoglobin, HbA1C, <= 12%
- •3.Subject with diagnosis of neuropathic foot ulcer by 10g monofilament test
- •4.Subject has adequate vascular perfusion of the affected limb, confirmed by Ankle-Brachial Index (ABI) >= 0.65 and <= 1.3
- •5.Presence of at least one DFU that meets all of the following criteria:
- •a.A full-thickness ulcer of Grade A1 as per Texas classification system;
- •b.Ulcer size (area) is >= 2 cm2 and <= 15 cm2 (post-debridement);
- •c.No exposed bone, tendon, muscle, ligament or joint capsule, and no tunneling, undermining, or sinus tracts;
- •6.Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Investigator
- •7.Subject, if female of child-bearing potential, has a negative urine pregnancy test at Screening and willing to use acceptable methods of contraception (birth control pills, barriers) or abstinence throughout the Study
- •8.Subject is able and willing to comply with Study procedures including the use of an off-loading device (as applicable for the location of the ulcer) and adhere to protocol during the Study in the opinion of Investigator
- •9.A Subject or LAR agrees to sign informed consent form and allow audio visual recording of consent, if applicable
排除标准
- •Subjects will not be eligible for enrolment in the Study if they meet any of the exclusion criteria listed below:
- •1.Actively infected ulcers with or without purulent discharge, ulcers with exposed bone or associated with osteomyelitis
- •2.Subjects with more than three ulcers below knee
- •3.Subjects with Target Ulcer requiring off-loading that cannot be effectively off-loaded; or unable to tolerate the off-loading method
- •4.Subject has ulcers caused by a disease other than diabetes, in the opinion of the Investigator
- •5.Ulcer, about which the Investigator is suspicious for cancer
- •6.Subjects with a gangrenous or ischemic ulcer
- •7.Subject with ulcer that in the opinion of the Investigator, may need amputation
- •8. Subject with Target ulcer where wound measurement is not possible, such as ulcers between toes
- •9.Body mass index (BMI) > 40 kg/m2
- •10.Laboratory values at Screening of: Hemoglobin < 10.0 g/dL, White Blood Cells (WBC) < 2.0 X 109 cells/L, Albumin < 2.5 g/dL, eGFR < 25 mL/min
- •11.Presence of any existing clinically significant medical condition(s) that, in the opinion of the Investigator, could interfere with wound healing
- •12.Subject has received or is currently receiving or scheduled to receive medication or therapies during the course of the Study such as Immunosuppressants, Revascularization surgery, Growth factors, Hyperbaric oxygen therapy (HBOT), Negative pressure wound therapy (NPWT), Bioengineered tissue or skin substitutes, Topical steroids, Investigational drug(s) or therapies
- •13.Subject with intolerance to β-blockers at any time in the past
- •14.Has any other factor which may, in the opinion of the Investigator, compromise participation and/or follow-up in the Study
研究者
相似试验
尚未招募
3 期
Effect of Eluxadoline in Comparison to Mebeverine for Treatment of Patients With Diarrhoea-Predominant Irritable Bowel SyndromeCTRI/2024/02/062593Sun Pharmaceutical Industries Limited
招募中
3 期
Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when given in combination with Paclitaxel in patients diagnosed with HER2 Positive Metastatic Breast CancerCTRI/2017/02/007892Glenmark Pharmaceuticals Ltd
已完成
3 期
A Clinical Trial to Evaluate the Efficacy, Safety of Fesoterodine Fumarate Extended Release Tablets 4 mg / 8 mg Versus Solifenacin Succinate Tablets 5 mg/10 mg in Adult Patients Diagnosed with Overactive Bladder with Symptoms of Urge Urinary Incontinence, Urgency, and Frequency.CTRI/2021/12/038596MSN Laboratories Private Limited216
招募中
3 期
Comparison of immunogenicity, safety and tolerability of Single Dose of Hepatitis A (Live) Vaccine obtained by Freeze-dried process from Sinopharm against BiovacTM-A (Freeze-dried Live Attenuated Vaccine from Wockhardt)in Healthy Indian Children.CTRI/2017/09/009760Sinopharm India Private Limited
已完成
不适用
This is a clinical trial to compare clinical efficacy, safety and tolerability of generic Diclofenac Sodium Topical Gel 1%, with Voltaren® Gel (a Diclofenac Sodium Topical Gel 1%) and Vehicle of Diclofenac Sodium Topical Gel 1% in subjects with osteoarthritis(degenerative joint disease) of the kneeCTRI/2015/09/006149Cipla Limited990